Viral infections

Acquired immune deficiency syndrome (AIDS) is one of the most serious diseases caused by viral infection in the modern era. Although current therapies based on targeting key processes of the human immunodeficiency virus (HIV) replication cycle are potent and selective, several clinical failures have been recorded due to the emergence of drug resistance. Hence, there is an urgent need for novel drugs and alternative therapeutic strategies, which are generally to be found in the design of more potent and selective inhibitors of entry/fusion, reverse transcriptase (RT), integrase (IN) and protease (PR) as well as compounds targeting HIV proteins such as the capsid (CA), nucleocapsid (NCp7), negative regulatory factor (Nef), virion infectivity factor (Vif) is currently considered a highly promising anti-HIV strategy. Also severe acute respiratory syndrome (SARS), HxNy influenza, avian influenza, hepatitis C, Dengue fever, adenoviruses and papilloma virus still lack effective treatments. In this respect, NP may serve as unique source of bioactive leads for developing effective therapeutic agents against these viruses. 

 

 

To access your WG2 please log in

MEMBERS

Juana Díez      (Group leader)
Leondios Kostrikis
Andreas Meyerhans
Carole Devaux
Virginie Fievez
Krzysztof Pyrc
Daren Hart
Andres Merits 
Sandra Liekens 
Ali Mirazimi 
Carolina Herrera
Javier Sanchez Cespedes